This inventor holds 25 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoffmann-La Roche Inc., Sanofi-A Ventis Deutschland Gmbh, Roche Innovation Center Copenhagen A/s. Active years: 2007-2026.
Company Filing History:
22 out of 5,024 
2 out of 1,855 
1 out of 46 
Years Active: 2007-2026
Areas of Expertise:
Title: Marius Hoener: A Pioneer in the Field of Oligonucleotide Innovations
Introduction
Marius Hoener, located in Basel, Switzerland, is a prolific inventor with an impressive portfolio of 22 patents. His work primarily focuses on innovative solutions in the realm of oligonucleotides and their applications, especially in medical fields. Hoener’s contributions have the potential to significantly impact treatments for genetic disorders.
Latest Patents
Among Marius Hoener's latest patents is a groundbreaking invention concerning oligonucleotides designed to induce paternal UBE3A expression. This invention holds promise for treating Angelman syndrome by enabling the expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in neurons. The technology involves targeting the suppressor of the UBE3A paternal allele through hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. This innovative approach not only demonstrates Hoener's proficiency in biotechnology but also his commitment to finding therapeutic pathways for complex genetic disorders.
Career Highlights
Throughout his career, Marius Hoener has worked with reputed companies including Hoffmann-La Roche Inc. and Sanofi-Aventis Deutschland GmbH. His experience in these organizations has paved the way for his advancements in the field of oligonucleotides and their therapeutic applications. His contributions are notable not only for the inventions themselves but also for how they address pressing medical needs.
Collaborations
During his professional journey, Hoener has had the opportunity to collaborate with esteemed colleagues such as Juergen Wichmann and Veronica Costa. These collaborations have enriched his research and expanded the breadth of his innovations, further supporting advancements in genetic therapies.
Conclusion
Marius Hoener exemplifies the spirit of innovation in the field of biotechnology, with a strong focus on oligonucleotide research. His patents signify crucial steps toward addressing genetic disorders such as Angelman syndrome, showcasing his dedication to enhancing therapeutic options. As he continues his work in this vital area, the scientific community awaits further developments that could transform the landscape of genetic treatments.